Urogynecology · Nov 4, 2026

Major Adverse Cardiovascular Events Following Vaginal Estrogen Therapy 2004–2023

By Rustia G, Abou-Zeki J, Murphy J et al.

Importance: This study reports on prescription patterns during years when estrogen use may have been influenced by a U.S. Food and Drug Administration black box warning. Objective: The objective of this study was to evaluate whether vaginal estrogen prescription for genitourinary syndrome of menopause (GSM) is associated with major adverse cardiovascular events (MACE). Study Design: This was a retrospective cohort analysis using the TriNetX database of women with GSM. MACE was evaluated using inverse probability of treatment weighted logistic regression and Cox proportional hazard models. High-risk patients had MACE 91 days to 2 years before the index; low-risk patients had no MACE during this period. Comparisons were made between women with and without vaginal estrogen prescription within 1 year of GSM diagnosis. Results: Between January 1, 2004, and May 16, 2023, 301,701 women were included in the analysis. Of these, 6,152 (2.0%) had a history of recent MACE. Overall, 159,776 (53%) received at least 1 estrogen (estradiol or conjugated estrogens) prescription following GSM diagnosis, of whom 81,446 (51%) only received vaginal estrogen. Compared with controls, the vaginal estrogen cohort had lower odds of MACE (odds ratio [OR]: 0.87, 95% confidence interval [CI]: 0.84–0.89) and no significant difference in MACE hazard (hazard ratio: 0.98, 95% CI: 0.95–1.01). Recent MACE history (OR: 12.3, 95% CI: 11.7–13.0) and obesity (OR: 1.25, 95% CI: 1.21–1.29; hazard ratio: 1.23, 95% CI: 1.19–1.27) were strongly associated with MACE. Conclusions: Recent MACE history was strongly associated with subsequent MACE. Vaginal estrogen prescription was associated with lower odds of MACE and no increase in MACE hazard.

doi.org/10.1097/spv.0000000000001949PubMed 42981118Populations

AgingResearch.News